Due to the difficulty of tissue sample collection, circulating tumor cells and cell-free DNA in plasma samples were also investigated to monitor the duration and magnitude of clinical response of patients receiving ALK-TKIs [28, 29]. The gene discussed is ALK; the disease is neoplasm.